ES2133316T3 - Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t. - Google Patents

Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t.

Info

Publication number
ES2133316T3
ES2133316T3 ES92905897T ES92905897T ES2133316T3 ES 2133316 T3 ES2133316 T3 ES 2133316T3 ES 92905897 T ES92905897 T ES 92905897T ES 92905897 T ES92905897 T ES 92905897T ES 2133316 T3 ES2133316 T3 ES 2133316T3
Authority
ES
Spain
Prior art keywords
falciparum
hepatic
epithopes
carriers
phases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92905897T
Other languages
English (en)
Inventor
Claudine Guerin-Marchand
Pierre Druilhe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Application granted granted Critical
Publication of ES2133316T3 publication Critical patent/ES2133316T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/822—Protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION CONCIERNE UNA MOLECULA O COMPOSICION POLIPEPTIDICA, CARACTERIZADA POR LA PRESENCIA EN SU ESTRUCTURA DE UNA O VARIAS SECUENCIAS PEPTIDICAS PORTADORAS DE TODO O PARTE, DE UNO O VARIOS, EPITOPE(S) T, Y SI SE PRESENTA EL CASO DE OTRO EPITOPES, EN ESPECIAL DE LOS EPITOPES B, CARACTERISTICOS DE LAS PROTEINAS QUE RESULTAN DE LA ACTIVIDAD INFECCIOSA DE P. FALCIPARUM EN LAS CELULAS HEPATICAS. CONCIERNE IGUALMENTE LA PUESTA EN OBRA DE LAS MOLECULAS EN UNOS ENSAYOS Y COFRE O KITS DE DIAGNOSTICO IN VITRO DEL PALUDISMO SOBRE UNA MUESTRA BIOLOGICA QUE PROVIENE DEL INDIVIDUO ENTRE LOS QUE LA ENFERMEDAD ESTA EN DESCUBRIR. LA INVENCION TIENE IGUALMENTE POR OBJETO LA UTILIZACION DE ESTAS MOLECULAS EN LA COMPOSICIONES DE VACUNAS CONTRA EL PALUDISMO.
ES92905897T 1991-02-05 1992-02-05 Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t. Expired - Lifetime ES2133316T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9101286A FR2672290B1 (fr) 1991-02-05 1991-02-05 Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.

Publications (1)

Publication Number Publication Date
ES2133316T3 true ES2133316T3 (es) 1999-09-16

Family

ID=9409373

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92905897T Expired - Lifetime ES2133316T3 (es) 1991-02-05 1992-02-05 Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t.

Country Status (10)

Country Link
US (5) US6319502B1 (es)
EP (1) EP0570489B1 (es)
AT (1) ATE179718T1 (es)
CA (3) CA2101924C (es)
DE (1) DE69229107T2 (es)
DK (1) DK0570489T3 (es)
ES (1) ES2133316T3 (es)
FR (1) FR2672290B1 (es)
GR (1) GR3030219T3 (es)
WO (1) WO1992013884A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
FR2735478B1 (fr) 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
ATE534669T1 (de) * 2002-05-28 2011-12-15 Omrix Biopharmaceuticals Inc Verfahren zum erhalten von anti-idiotyp antikörpern
WO2004044167A2 (en) * 2002-11-12 2004-05-27 Walter Reed Army Institute Of Research Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
KR101035111B1 (ko) * 2004-06-30 2011-05-19 주식회사 엘지생명과학 말라리아 플라스모듐 팔시파룸의 면역학적 측정방법 및이에 사용되는 측정 수단
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EA020950B1 (ru) 2007-09-17 2015-03-31 Баррик Гольд Корпорейшн Способ усовершенствования восстановления золота из двойных тугоплавких золотосодержащих руд
US8262770B2 (en) 2007-09-18 2012-09-11 Barrick Gold Corporation Process for controlling acid in sulfide pressure oxidation processes
US7922788B2 (en) * 2007-09-18 2011-04-12 Barrick Gold Corporation Process for recovering gold and silver from refractory ores
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CN103491979B (zh) 2010-12-06 2016-12-21 马尔瓦有限责任公司 基于来自恶性疟原虫的红细胞前期抗原的疟疾疫苗
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569722B2 (en) * 1983-01-28 1988-02-18 Saramane Pty Ltd Expression of plasmodium falciparum polypeptides from cloned cdna
IL76338A (en) * 1984-09-11 1994-08-26 Saramane Pty Ltd Plasmodium plasmodium immunogenic polypeptides, AND molecules encoding them, a method for preparing the polypeptides and preparations containing the polypeptide
IL78476A0 (en) * 1985-04-11 1986-08-31 Inst Medical W & E Hall Highly repetitive antigens of plasmodium falciparum
EP0297110A4 (en) * 1986-03-14 1989-12-19 Saramane Pty Ltd POLYPEPTIDES WITH IMMUNE AGAINST MALARIA.
FR2672290B1 (fr) * 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US6270771B1 (en) * 1988-10-06 2001-08-07 Institut Pasteur Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes
FR2610631B1 (fr) * 1987-02-09 1989-11-24 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
AU4661889A (en) * 1988-11-30 1990-06-26 Biomedical Research Institute A novel malarial sporozoite and exoerythrocytic peptide antigen
FR2645877B1 (fr) * 1989-04-12 1991-07-05 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum au niveau du stade sporozoite et dans les hepatocytes
GB9020438D0 (en) * 1990-09-19 1990-10-31 Imperial College Plasmodium liver stage antigens
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US5602831A (en) * 1995-03-31 1997-02-11 Seiko Communications Systems, Inc. Optimizing packet size to eliminate effects of reception nulls
FR2735478B1 (fr) * 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
CN1244126A (zh) * 1997-01-21 2000-02-09 纽约大学 用于抗疟疾疫苗的通用t细胞表位
CA2337754C (en) * 1998-08-21 2011-05-24 Altaf A. Lal Recombinant multivalent malarial vaccine against plasmodium falciparum
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
WO2002092628A2 (fr) * 2001-05-16 2002-11-21 Institut Pasteur Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
AU2003285932A1 (en) * 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria

Also Published As

Publication number Publication date
FR2672290B1 (fr) 1995-04-21
HK1014012A1 (en) 1999-09-17
EP0570489B1 (fr) 1999-05-06
WO1992013884A1 (fr) 1992-08-20
GR3030219T3 (en) 1999-08-31
EP0570489A1 (fr) 1993-11-24
US20030064075A1 (en) 2003-04-03
FR2672290A1 (fr) 1992-08-07
ATE179718T1 (de) 1999-05-15
DE69229107T2 (de) 1999-12-16
US20020041882A1 (en) 2002-04-11
US6319502B1 (en) 2001-11-20
CA2101924A1 (fr) 1992-08-06
US7087231B2 (en) 2006-08-08
US20080213795A1 (en) 2008-09-04
CA2101924C (fr) 2005-06-28
US7332595B2 (en) 2008-02-19
CA2495581C (fr) 2008-10-21
US20060182769A1 (en) 2006-08-17
US7438917B2 (en) 2008-10-21
CA2495581A1 (fr) 1992-08-20
DK0570489T3 (da) 2000-01-03
CA2638662A1 (fr) 1992-08-20
DE69229107D1 (de) 1999-06-10

Similar Documents

Publication Publication Date Title
ES2133316T3 (es) Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t.
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
AR005945A1 (es) Composicion farmaceutica para la modulacion inmunitaria
ES2172773T3 (es) Procedimiento de dosificado de linfocitos t especificos para un peptido.
PE20030527A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
HU9904549A (en) Vaccines
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
ATE331530T1 (de) Proteasom-influenzavirus-impfstoffzusammensetzu g
ES2098029T5 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
CR8423A (es) Analogos nucleotidos clase c con potencia inmunoestimulante mejorada
ES2054696T3 (es) Agente viral de la hepatitis nanb, antigen y reactivo inmunologico.
ES2123558T3 (es) Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc.
ES2141750T3 (es) Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno.
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
AR053286A2 (es) Cultivo de celulas de una cepa derivada de una cepa progenitra de una especie de neospora, vacuna que las contiene, metodos para preparar dicho cultivo, metodo para preparar una vacuna con dicho cultivo, metodo para vacunar un mamifero con dicha vacuna y vacuna que comprende dichas celulas
CO4520254A1 (es) Vacunas contra tumores y procedimiento para su produccion
ES2052699T3 (es) Vacuna contra la gripe.
AR071741A1 (es) Vacunas contra la malaria
ES2137160T3 (es) Lipopeptidos inductores de los linfocitos t-citotoxicos y utilizacion como vacunas.
ES2144507T3 (es) Potencializador de la actividad pesticida de bacillus.
Takemoto et al. Immunofluorescent demonstration of polyoma tumor antigen in lytic infection of mouse embryo cells
AR022773A1 (es) Emulsiones pit y procedimiento para la elaboracion de emulsiones de pesticidas
HN2002000366A (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma
DE69836976D1 (de) Neospora impstoff

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 570489

Country of ref document: ES